Medicinal cannabis producer Bod (ASX: BDA) is off to a strong start in 2020, reporting January as its third-largest month on record.
The group filled 373 prescriptions of its MediCabilis during the month, bringing the total number of prescriptions of its drug to 2,330 in the 12 months since launch.
"Growth in prescription numbers for January is very encouraging and we are pleased to witness this steady increase in sales," says Bod CEO Jo Patterson.
The company expects to enter into the UK this month, which should boost its prescription numbers even higher.
Bod will also launch two new products 2.5 per cent and 10 per cent MediCabilis products which will likely grab a further 32 per cent of the prescription market.
The cannabis producer says this segment is less competitive, given the lack of CBD isolate products available to patients and physicians.
"We have a great opportunity and larger sales footprint," says Patterson.
"Bod is therefore well primed to drive prescription number growth."
Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.
Business News Australia
Get our daily business news
Sign up to our free email news updates.
Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support